top of page

11/11/22

Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern

Mazzaferri F, Mirandola M, Savoldi A, De Nardo P, Morra M, Tebon M,  Armellini M, De Luca G, Calandrino L, Sasset L, D'Elia D, Sozio E,  Danese E, Gibellini D, Monne I, Scroccaro G, Magrini N, Cattelan A,  Tascini C; MANTICO Working Group, Tacconelli E.

Elife

Recent in-vitro data have shown that the activity of monoclonal  antibodies (mAbs) targeting severe acute respiratory syndrome  coronavirus 2 (SARS-CoV-2) varies according to the variant of concern  (VOC). No studies have compared the clinical efficacy of different mAbs  against Omicron VOC.

bottom of page